华北制药
(600812)
| 流通市值：101.57亿 | | | 总市值：101.57亿 |
| 流通股本：17.16亿 | | | 总股本：17.16亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 5,275,037,790.2 | 2,574,254,051.92 | 9,869,575,819.11 | 7,560,235,670.39 |
| 营业收入 | 5,275,037,790.2 | 2,574,254,051.92 | 9,869,575,819.11 | 7,560,235,670.39 |
| 二、营业总成本 | 5,064,452,841.41 | 2,469,225,602.07 | 9,602,162,210.85 | 7,395,586,299.65 |
| 营业成本 | 3,712,471,185.76 | 1,816,338,278.92 | 6,714,658,593.44 | 5,272,198,266.78 |
| 税金及附加 | 58,901,920.86 | 26,799,221.61 | 109,275,550.51 | 77,366,304.85 |
| 销售费用 | 682,307,914.65 | 321,958,401.87 | 1,433,292,527.42 | 1,052,291,747.95 |
| 管理费用 | 264,978,738.01 | 134,047,050.91 | 581,885,940.9 | 415,243,846.33 |
| 研发费用 | 169,073,874.09 | 80,967,533.71 | 337,275,440.94 | 251,674,097.83 |
| 财务费用 | 176,719,208.04 | 89,115,115.05 | 425,774,157.64 | 326,812,035.91 |
| 其中:利息费用 | 190,640,852.41 | 97,396,371.32 | 458,698,019.11 | 345,915,986.61 |
| 其中:利息收入 | 13,034,013.73 | 6,554,100.01 | 25,255,785.32 | 18,449,560.56 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 26,285,765.54 | 7,596,720.83 | 46,164,658.18 | 33,415,822.41 |
| 资产处置收益 | -9,846.67 | 4,253.94 | 444,156.56 | 440,884.14 |
| 资产减值损失(新) | 7,432,452.04 | 6,614,126.09 | -16,374,073.77 | 8,350,790.94 |
| 信用减值损失(新) | -38,886,024.62 | -21,594,563.99 | -22,675,856 | -6,417,154.9 |
| 其他收益 | 8,366,394.1 | 5,266,449.31 | 36,708,667.71 | 22,655,374.24 |
| 四、营业利润 | 213,773,689.18 | 102,915,436.03 | 311,681,160.94 | 223,095,087.57 |
| 加:营业外收入 | 633,098.54 | 375,653.51 | 6,936,839.19 | 3,339,164.23 |
| 减:营业外支出 | 370,543.27 | 138,827.07 | 8,785,487.37 | 3,458,318.97 |
| 五、利润总额 | 214,036,244.45 | 103,152,262.47 | 309,832,512.76 | 222,975,932.83 |
| 减:所得税费用 | 51,749,387.85 | 26,526,600.48 | 94,865,994.43 | 76,535,187.12 |
| 六、净利润 | 162,286,856.6 | 76,625,661.99 | 214,966,518.33 | 146,440,745.71 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 162,286,856.6 | 76,625,661.99 | 214,966,518.33 | 146,440,745.71 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 123,497,402.89 | 57,491,586.04 | 126,992,370.2 | 102,463,641.21 |
| 少数股东损益 | 38,789,453.71 | 19,134,075.95 | 87,974,148.13 | 43,977,104.5 |
| 扣除非经常损益后的净利润 | 119,946,433.69 | 55,215,276.48 | 112,879,831.22 | 82,555,825.6 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.07 | 0.03 | 0.07 | 0.06 |
| (二)稀释每股收益 | 0.07 | 0.03 | 0.07 | 0.06 |
| 八、其他综合收益 | -412,469.02 | 39,722.88 | 1,601,601.48 | -150,201.56 |
| 归属于母公司股东的其他综合收益 | -412,469.02 | 39,722.88 | 1,601,601.48 | -150,201.56 |
| 九、综合收益总额 | 161,874,387.58 | 76,665,384.87 | 216,568,119.81 | 146,290,544.15 |
| 归属于母公司股东的综合收益总额 | 123,084,933.87 | 57,531,308.92 | 128,593,971.68 | 102,313,439.65 |
| 归属于少数股东的综合收益总额 | 38,789,453.71 | 19,134,075.95 | 87,974,148.13 | 43,977,104.5 |
| 公告日期 | 2025-08-14 | 2025-04-24 | 2025-03-28 | 2024-10-26 |
| 审计意见(境内) | | | 标准无保留意见 | |